Compare Neurocrine Biosciences Inc (NBIX) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Xylem, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Xylem, Inc. trades at $102.71 (market cap $23.81B). The key difference: Xylem, Inc. is the larger of the two by market cap, and Xylem, Inc. pays a 1.69% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Xylem, Inc. for 50 Days on average.
| NBIX | XYL | |
|---|---|---|
Market Cap | $14.36B | $23.81B |
Volume | 1,237,180 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $185.50 | $152.95 |
52-Week Low | $123.10 | $100.92 |
Typical Hold Time | 23 Days | 50 Days |
Enterprise Value | $14.37B | $25.59B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
XYL trades at $101.99, up 0.16% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 27, 2026. Revenue grew to $9.04B in 2025, and net income margin improved to 10.59%. Recent acquisitions of Cornell Pump and Roper Pump aim to strengthen its industrial water solutions presence.
The outlook is supported by solid fundamentals and a consensus price target of $149.13, implying significant upside. Risks include China market weakness and higher debt from recent note offerings. Analyst sentiment is mixed with 47.5% buy ratings, but institutional interest remains strong, as seen in Bank of America's new position in Q2 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
